Catalyst Wire Dossier Catalyst Wire Dossier

Yttrium-90 ibritumomab tiuxetan

yttrium-90 ibritumomab tiuxetan · GlaxoSmithKline
Drug timelines are a Plus or Pro feature.

8 regulatory and trial events tracked for Yttrium-90 ibritumomab tiuxetan, covering 2012-04-03 to 2021-06-18. Get the full timeline:

Most recent: Clinical Trial Update: Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients [Phase 1, Phase 2]

See pricing